Am J Perinatol 2019; 36(01): 022-026
DOI: 10.1055/s-0038-1636501
SMFM Fellowship Series Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Hyperglycosylated hCG and Placenta Accreta Spectrum

Brett D. Einerson
1   Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of Utah Health, Salt Lake City, Utah
2   Intermountain Healthcare, Salt Lake City, Utah
,
Alli Straubhar
3   Department of Obstetrics and Gynecology, University of Utah Health, Salt Lake City, Utah
,
Sean Soisson
4   Division of Genetic Epidemiology, Department of Internal Medicine, University of Utah Health, Salt Lake City, Utah
,
Kathryn Szczotka
3   Department of Obstetrics and Gynecology, University of Utah Health, Salt Lake City, Utah
,
Mark K. Dodson
5   Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Utah Health, Salt Lake City, Utah
,
Robert M. Silver
1   Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of Utah Health, Salt Lake City, Utah
2   Intermountain Healthcare, Salt Lake City, Utah
,
Andrew P. Soisson
5   Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Utah Health, Salt Lake City, Utah
› Author Affiliations
Further Information

Publication History

14 August 2017

26 January 2018

Publication Date:
28 February 2018 (online)

Abstract

Objective We aimed to evaluate the relationship between hyperglycosylated human chorionic gonadotropin (hCG-H) and placenta accreta spectrum (PAS) in the second and third trimesters of pregnancy.

Study Design This was a case–control study of PAS and controls. hCG-H was measured in the second and third trimesters of pregnancy in women with pathologically confirmed cases of PAS and in gestational age-matched controls without PAS. We compared serum hCG-H levels in cases and controls, calculated summary statistics for diagnostic accuracy, and used receiver operating characteristic (ROC) curves to define an optimal cut-point for diagnosis of PAS using hCG-H.

Results Thirty case samples and 30 control samples were evaluated for hCG-H. Mean hCG-H was lower in the case compared with control group (7.8 ± 5.9 μg/L vs. 11.8 ± 8.8 μg/L, p = 0.03). At an optimal cut-point for hCG-H of ≤7.6 μg/L, the sensitivity, specificity, positive likelihood ratios, negative likelihood ratios, and area under the ROC curve were 66.7%, 69.7%, 2.20%, 0.48%, and 0.68%, respectively.

Conclusion Hyperglycosylated hCG levels in the second and third trimesters of pregnancy were lower in patients with PAS than in controls, but hCG-H showed only modest capability as a diagnostic test for PAS.

 
  • References

  • 1 Clark SL, Koonings PP, Phelan JP. Placenta previa/accreta and prior cesarean section. Obstet Gynecol 1985; 66 (01) 89-92
  • 2 Silver RM, Landon MB, Rouse DJ. , et al; National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Maternal morbidity associated with multiple repeat cesarean deliveries. Obstet Gynecol 2006; 107 (06) 1226-1232
  • 3 Gyamfi-Bannerman C, Gilbert S, Landon MB. , et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Maternal-Fetal Medicine Units (MFMU) Network. Risk of uterine rupture and placenta accreta with prior uterine surgery outside of the lower segment. Obstet Gynecol 2012; 120 (06) 1332-1337
  • 4 Eller AG, Porter TF, Soisson P, Silver RM. Optimal management strategies for placenta accreta. BJOG 2009; 116 (05) 648-654
  • 5 Wright JD, Pri-Paz S, Herzog TJ. , et al. Predictors of massive blood loss in women with placenta accreta. Am J Obstet Gynecol 2011; 205 (01) 38.e1-38.e6
  • 6 Balayla J, Bondarenko HD. Placenta accreta and the risk of adverse maternal and neonatal outcomes. J Perinat Med 2013; 41 (02) 141-149
  • 7 Shamshirsaz AA, Fox KA, Salmanian B. , et al. Maternal morbidity in patients with morbidly adherent placenta treated with and without a standardized multidisciplinary approach. Am J Obstet Gynecol 2015; 212 (02) 218.e1-218.e9
  • 8 Shamshirsaz AA, Fox KA, Erfani H. , et al. Multidisciplinary team learning in the management of the morbidly adherent placenta: outcome improvements over time. Am J Obstet Gynecol 2017; 216 (06) 612.e1-612.e5
  • 9 Warshak CR, Ramos GA, Eskander R. , et al. Effect of predelivery diagnosis in 99 consecutive cases of placenta accreta. Obstet Gynecol 2010; 115 (01) 65-69
  • 10 Bowman ZS, Eller AG, Kennedy AM. , et al. Interobserver variability of sonography for prediction of placenta accreta. J Ultrasound Med 2014; 33 (12) 2153-2158
  • 11 Evans J. Hyperglycosylated hCG: a unique human implantation and invasion factor. Am J Reprod Immunol 2016; 75 (03) 333-340
  • 12 Cole LA, Dai D, Butler SA, Leslie KK, Kohorn EI. Gestational trophoblastic diseases: 1. Pathophysiology of hyperglycosylated hCG. Gynecol Oncol 2006; 102 (02) 145-150
  • 13 Cole LA, Laidler LL, Muller CY. USA hCG reference service, 10-year report. Clin Biochem 2010; 43 (12) 1013-1022
  • 14 Cole LA. Biological functions of hCG and hCG-related molecules. Reprod Biol Endocrinol 2010; 8: 102-114
  • 15 Liu X. Classification accuracy and cut point selection. Stat Med 2012; 31: 2676-2686
  • 16 Sasaki Y, Ladner DG, Cole LA. Hyperglycosylated human chorionic gonadotropin and the source of pregnancy failures. Fertil Steril 2008; 89 (06) 1781-1786
  • 17 Cole LA. hCG and hyperglycosylated hCG in the establishment and evolution of hemochorial placentation. J Reprod Immunol 2009; 82 (02) 112-118
  • 18 Evans J, Salamonsen LA, Menkhorst E, Dimitriadis E. Dynamic changes in hyperglycosylated human chorionic gonadotrophin throughout the first trimester of pregnancy and its role in early placentation. Hum Reprod 2015; 30 (05) 1029-1038
  • 19 Warshak CR, Eskander R, Hull AD. , et al. Accuracy of ultrasonography and magnetic resonance imaging in the diagnosis of placenta accreta. Obstet Gynecol 2006; 108 (3 Pt 1): 573-581
  • 20 Dwyer BK, Belogolovkin V, Tran L. , et al. Prenatal diagnosis of placenta accreta: sonography or magnetic resonance imaging?. J Ultrasound Med 2008; 27 (09) 1275-1281
  • 21 Wong HS, Cheung YK, Zuccollo J, Tait J, Pringle KC. Evaluation of sonographic diagnostic criteria for placenta accreta. J Clin Ultrasound 2008; 36 (09) 551-559
  • 22 Shih JC, Palacios Jaraquemada JM, Su YN. , et al. Role of three-dimensional power Doppler in the antenatal diagnosis of placenta accreta: comparison with gray-scale and color Doppler techniques. Ultrasound Obstet Gynecol 2009; 33 (02) 193-203
  • 23 Esakoff TF, Sparks TN, Kaimal AJ. , et al. Diagnosis and morbidity of placenta accreta. Ultrasound Obstet Gynecol 2011; 37 (03) 324-327
  • 24 Bowman ZS, Eller AG, Kennedy AM. , et al. Accuracy of ultrasound for the prediction of placenta accreta. Am J Obstet Gynecol 2014; 211 (02) 177.e1-177.e7
  • 25 Bour L, Placé V, Bendavid S. , et al. Suspected invasive placenta: evaluation with magnetic resonance imaging. Eur Radiol 2014; 24 (12) 3150-3160
  • 26 D'Antonio F, Iacovella C, Palacios-Jaraquemada J, Bruno CH, Manzoli L, Bhide A. Prenatal identification of invasive placentation using magnetic resonance imaging: systematic review and meta-analysis. Ultrasound Obstet Gynecol 2014; 44 (01) 8-16
  • 27 Riteau A-S, Tassin M, Chambon G. , et al. Accuracy of ultrasonography and magnetic resonance imaging in the diagnosis of placenta accreta. PLoS One 2014; 9 (04) e94866-e94869